An interview video putting the peptide question to a nurse practitioner. The title gives no detail on which peptides they cover or what evidence comes up.
Recap by typeshit. Full story at YouTube.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
She says the cause is a calorie surplus: some patients still manage high calorie foods and aren't exercising enough while on the drugs.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
An unsourced alert says compounded injectables, sermorelin included, face scrutiny over sterility. It names no regulator or official action.
Philstar Life has a roundup of where Eli Lilly's experimental retatrutide stands in 2026. Specifics were not available here, so tap through for the details.
Loading…